{'fraction_non_alphanumeric': 0.045342533267619514, 'fraction_numerical': 0.026121241991128634, 'mean_word_length': 4.546448087431694, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
346-OR: Race/Ethnicity-Specific Relationships of Physical Markers of Adiposity to Clamp-Measured Insulin Sensitivity (IS) and ß-Cell Function (ßCF) in Obese Youth

Physical markers of adiposity including BMI, WC and WHtR have been utilized as physical surrogates of IS and βCF to examine type 2 diabetes risk but without attention to race/ethnicity specific differences. Herein, we examined race-specific differences in the relationships between those physical surrogates and clamp-measured IS and βCF in obese African American (AA) vs. American White (AW) youth. A total of 183 obese youth (age 14.6 ± 0.1 yrs [SE]) completed a hyperinsulinemic-euglycemic clamp to evaluate peripheral IS and a hyperglycemic clamp to measure 1st-phase insulin (1st-PhI) . In AW, BMI, WC and WHtR correlated significantly with peripheral IS and 1st-PhI while in AA with only peripheral IS (Table) . The relationships of BMI to peripheral IS and 1st-PhI were stronger in AW vs. AA youth, with no differences in the correlation coefficients by race for WC and WHtR (Table) . There was a larger decrease in peripheral IS from the lowest to the highest tertiles of BMIs in AW vs. AA youth (63 vs. 39%, interaction p<0.01) , with no interaction on 1st-PhI.The strong relationship of BMI with IS and 1st-PhI in AW but not AA youth may suggest that other factors besides BMI may play a role in the insulin resistance/hyperinsulinemia reported in AA youth. In AW youth, increases in BMI may be more detrimental for reductions in insulin sensitivity than is the case for AA youth.
 
 
 
 J.Rosenberg: None. W.Cho: None. S.A.Arslanian: Advisory Panel; Eli Lilly and Company, Novo Nordisk, Other Relationship; AstraZeneca, Research Support; Eli Lilly and Company, Novo Nordisk. J.Kim: n/a.
 
 
 
 National Institute of Child Health and Human Development grant (K24-HD01357 and R01-HD27503) National Center for Advancing Translational Sciences Clinical and Translational Science Award (UL1TR000005) National Center for Research Resources grant (UL1RR024153)
